Table 3.
Seroconversion rates, crude and mutually adjusted odds ratios (cOR, aOR) including the 95% confidence interval
| Predictors | Seroconversion, at least a fourfold increase in antibodies (SCR4) | Seroconversion, at least a twofold increase in antibodies (SCR2) | ||||||
|---|---|---|---|---|---|---|---|---|
| Rate (%) | cOR | aOR | P | Rate (%) | cOR | aOR | P | |
| Sex | ||||||||
| Male | 70.0 (60.0–78.8) | 92.0 (84.8–96.5) | ||||||
| Female | 69.0 (59.0–77.9) | 0.95 (0.52–1.74) | 1.22 (0.26–5.78) | 0.800 | 90.0 (82.4–95.1) | 0.78 (0.30–2.07) | 0.53 (0.07–4.25) | 0.554 |
| Vaccine | ||||||||
| Tetavax | 68.0 (57.9–77.0) | 89.0 (81.2–94.4) | ||||||
| Vacteta | 71.0 (61.1–79.6) | 1.15 (0.63–2.10) | 0.89 (0.22–3.60) | 0.871 | 93.0 (86.1–97.1) | 1.64 (0.61–4.42) | 0.90 (0.14–5.85) | 0.916 |
| Smoker | ||||||||
| No | 73.0 (65.3–79.7) | 90.6 (84.9–94.6) | ||||||
| Yes | 56.1 (39.7–71.5) | 0.47 (0.23–0.96) | 0.11 (0.02–0.69) | 0.019 | 92.7 (80.1–98.5) | 1.32 (0.36–4.79) | 4.13 (0.40–42.12) | 0.232 |
| Concomitant medication | ||||||||
| No | 68.5 (59.7–76.5) | 89.8 (83.1–94.4) | ||||||
| Yes | 71.2 (59.4–81.2) | 1.14 (0.61–2.14) | 1.63 (0.33–8.14) | 0.549 | 93.2 (84.7–97.7) | 1.55 (0.53–4.54) | 2.64 (0.29–24.32) | 0.392 |
| Related adverse events | ||||||||
| No | 69.4 (61.2–76.8) | 88.9 (82.6–93.5) | ||||||
| Yes | 69.6 (55.9–81.2) | 1.01 (0.52–1.97) | 2.93 (0.42–20.40) | 0.278 | 96.4 (87.7–99.6) | 3.38 (0.75–15.19) | 17.3 (0.71–421.57) | 0.080 |
| Age (years) | ||||||||
| ⩽43.8 | 73.7 (63.9–82.1) | 92.9 (86.0–97.1) | ||||||
| >43.8 | 65.3 (55.2–74.5) | 0.67 (0.37–1.23) | 0.99 (0.91–1.08) | 0.897 | 89.1 (81.3–94.4) | 0.62 (0.23–1.68) | 0.95 (0.85–1.06) | 0.347 |
| BMI (kg/m2) | ||||||||
| ⩽25.8 | 66.7 (56.5–75.8) | 91.9 (84.7–96.4) | ||||||
| >25.8 | 72.3 (62.5–80.7) | 1.30 (0.71–2.38) | 1.31 (1.08–1.60) | 0.007 | 90.1 (82.5–95.1) | 0.80 (0.30–2.12) | 0.98 (0.79–1.20) | 0.815 |
| Pre-vaccination period (years) | ||||||||
| ⩽12.6 | 71.4 (61.4–80.1) | 92.9 (85.8–97.1) | ||||||
| >12.6 | 67.6 (57.7–76.6) | 0.84 (0.46–1.53) | 0.54 (0.32–0.91) | 0.021 | 89.2 (81.5–94.5) | 0.64 (0.24–1.71) | 0.61 (0.31–1.19) | 0.146 |
| Pre-vaccination GMC (IU/ml) | ||||||||
| ⩽1.2 | 100.0 (96.5–100) | 100.0 (96.5–100) | ||||||
| >1.2 | 37.1 (27.5–47.5) | 0.00 (0.00–0.02) | 0.01 (0.00–0.06) | <0.001 | 81.4 (72.3–88.6) | 0.00 (0.00–0.16) | 0.21 (0.11–0.40) | <0.001 |
| Post-vaccination period (days) | ||||||||
| ⩽28 | 69.2 (59.5–77.7) | 89.7 (82.3–94.8) | ||||||
| >28 | 69.9 (59.5–79.0) | 1.04 (0.57–1.89) | 1.40 (0.95–2.08) | 0.088 | 92.5 (85.1–96.9) | 1.41 (0.52–3.79) | 1.42 (0.87–2.29) | 0.157 |
P, statistical significance determined by logistic regression.